Travere Therapeutics TVTX
NASDAQ TVTX
$56.93 +0.08 (+0.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Travere Therapeutics (TVTX) Gains from Sales and Divestitures (2016)

Updated

Travere Therapeutics (TVTX) reported Gains from Sales and Divestitures of -$62,000 for Q4 2016.

Analysis

Travere Therapeutics (TVTX) Gains from Sales and Divestitures (2016) Analysis & Trends

  • By year, Gains from Sales and Divestitures came in at -$112,000 in FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Travere Therapeutics 5.36 Bn 4.96 Bn 167.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 -62,000.00
API Access

Travere Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TVTX&period=max&api_key=YOUR_API_KEY